中皮腫における免疫微小環境と遺伝子発現プロファイリング (Imaging-Meso)
免疫微小環境の特性評価と遺伝子発現プロファイリングから、胸膜および腹膜中皮腫における新薬試験まで: イメージング - 中皮腫研究
Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options and a dismal prognosis. The main unmet medical need in PPM is the lack of a treatment sequence for affected patients. The advent of immune checkpoint inhibitors has changed the first line treatment of PPM, thanks to the improvement in survival achieved by the combination of ipilimumab and nivolumab that are currently approved for non-epithelioid histology in our Country.
PPM is characterized by a large heterogeneity of the genomic landscape, which is mainly characterized by the loss of tumour suppressor genes and mutations in DNA repair genes and by an "altered- suppressed" or "excluded" tumor immune microenvironment (TIME).
The goal of this project is to improve the immune-biological and molecular stratification of PPM subgroups that can lead to the identification of different personalized treatment approaches. PPM patients (N=220) will be retrospectively (N=150) and prospectively (N=70) recruited from the coordinator center and 6 participating Italian centers. Treatment-naïve tumor samples will be collected and analyzed by bulk gene expression and spatial whole transcriptome analysis, and by 9-color multiplex immunofluorescence.
New targets or actionable pathways potentially emerging from such studies will be finally assessed and validated in patient-derived organoids/xenografts that accurately reflect PPM tumorigenesis.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Alessandria、イタリア、15121
- Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
-
Bergamo、イタリア
- Asst Papa Giovanni Xxiii Bergamo
-
Genova、イタリア
- Ircss Ospedale Policlinico San Martino
-
Milan、イタリア
- Asst Grande Ospedale Metropolitano Niguarda-Milano
-
Milan、イタリア
- Fondazione Ircss Istituto Nazionale Dei Tumori Di Milano
-
Padova、イタリア、35128
- Istituto Oncologico Veneto
-
Parma、イタリア、43126
- Azienda Ospedaliera-Universitaria di Parma
-
Verona、イタリア
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
Milano
-
Rozzano、Milano、イタリア、20089
- Istituto Clinico Humanitas
-
-
Pordenone
-
Aviano、Pordenone、イタリア、33081
- Centro di Riferimento Oncologico (CRO) IRCCS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
220 PPM patients will be enrolled in 7 Centers, 150 retrospectively and 70 prospectively.
説明
Inclusion Criteria:
- Patients with Mesothelioma of the Pleura and Peritoneum
- Age greater than 18 years of age
- Patients undergoing surgery will require both biopsy and surgical sampling material
- Pathologist's confirmation of the presence of tumor sections in the excised specimens
- Patients in follow-up from active cancer treatment for at least 6 months
Exclusion Criteria:
- Inadequacy of biological material for analysis under study
- Patients not amenable to active oncologic treatment
- Patients lost to follow-up before 6 months after the end of active oncologic treatment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:OTHER
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary outcome
時間枠:Through study completion, an average of 3 years
|
PPM treatment-naïve tumor samples and classification in different clusters according to the differential expression of molecular and gene signatures by Gene expression profile (GEP) analysis. |
Through study completion, an average of 3 years
|
|
Primary outcome
時間枠:Through study completion, an average of 3 years
|
Identification of molecular and immune signatures predictive of resistance or sensitivity to systemic anticancer drugs: chemotherapy or immunotherapy administered as first line treatment by spatial whole transcriptome analysis. |
Through study completion, an average of 3 years
|
|
Primary outcome
時間枠:Through study completion, an average of 3 years
|
PPM surgical specimens and comparison with GEP in matched treatment-naïve tumor samples will be performed by gene expression profile analysis with GEP analysis. |
Through study completion, an average of 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary outcome
時間枠:Through study completion, an average of 3 years
|
Characterization and quantification of immune cell distribution and their spatial relationships in treatment naïve tumor samples of PPM patients will be performed by a 9-color multiplex immunofluorescence (mIF) analysis. |
Through study completion, an average of 3 years
|
|
Secondary outcome
時間枠:Through study completion, an average of 3 years
|
Immune phenotypes defined by mIF and the immune signatures identified by GEP analyses will be performed in each treatment-naïve tumor sample. |
Through study completion, an average of 3 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Third outcome
時間枠:Through study completion, an average of 3 years
|
In vitro and in vivo models of PPM for the investigation of activated signatures, new therapeutic targets and drug sensitivity tests. will be performed by:
|
Through study completion, an average of 3 years
|
協力者と研究者
捜査官
- 主任研究者:Giulia Pasello, MD、Istituto Oncologico Veneto IOV IRCCS
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。